Google
Trusted Resources: News & Events
Latest announcements and gatherings
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)
GBT440 is First Potential Treatment for SCD To Be Accepted for PRIME.
PRIME Designation Allows for Frequent and Early Interactions with the Agency Aimed at Assisting Accelerated Evaluation and ApprovalF.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the European Medicines Agency (EMA) has determined that GBT440 for the treatment of sickle cell disease is eligible for its Priority Medicines (PRIME) program. The PRIME program is a new regulatory mechanism that provides for early and proactive EMA support to medicine developers to help patients benefit as early as possible from innovative new products that have demonstrated the potential to significantly address an unmet medical need.
+myBinderRelated Content
-
Providing Expert Care for Pregnant Sickle Cell Patienthttps://www.youtube.com/watch?v=rTebitxq...
-
Nirmish Shah, MDAs director of Duke’s sickle cell tran...
-
Texas Children’s HospitalThe Sickle Cell Center at Texas Children...
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
-
Yale New Haven HospitalMedical teams at Yale New Haven Hospital...
-
Betty Pace, MDDr. Betty Pace is a pediatric hematologi...
-
Conversation With Women in the Sickle Cell CommunitySickle Cell Project of NW Ohio at Neighb...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.